Cases & Deals

  • Home
  • Practices
  • AbbVie successfully defends patents related to HUMIRA® against IPR petitions filed by Amgen

Share

AbbVie successfully defends patents related to HUMIRA® against IPR petitions filed by Amgen

January 2016

Client(s) AbbVie Inc.

Jones Day served as co-counsel in the successful defense of AbbVie Inc. in two IPRs brought by Amgen in connection with U.S. Patent Nos. 8,916,157 and 8,916,158 related to AbbVie's blockbuster antibody therapeutic, HUMIRA®. Following filing of the Patent Owner's Preliminary Responses by AbbVie, the PTAB denied institution of both IPRs.

Amgen Inc. v. AbbVie Biotechnology Ltd. et al., IPR2015-01514, -01517 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.